Materials and methods
uterine abnormality
ECTOPIC PREGNANCY, EVENTS, MISCARRIAGE, ANEUPLOIDY
A decision tree model based on data from the CESE-PGS trial was developed using the TreeAge Pro Suite 2011 software (TreeAge Software, Inc., Williamstown, MA, USA) (Fig. 
Decision tree model based on the CESE-PGS trial. Note: IVF, In Vitro Fertilization; PGT-A, Preimplantation genetic testing for Aneuploidy. As indicated in Fig. 1, one embryo refers to one subsequent embryo transfer cycle initiated, two embryos refer to two subsequent embryo transfer cycles initiated, and so on. The “+” stands for the same decision structure as above. Nodes within the model are marked by circles, triangles define endpointsThe model incorporated main clinical events that were critical and would incur costs were chosen including PGT-A, blastocyst transfer, clinical pregnancy, miscarriage, and live birth. For both groups, each transfer had 3 distinct possible outcomes: not pregnant, clinical miscarriage, and live birth. The analysis of the decision tree model allowed us to obtain the probability of pregnancy, miscarriage, and live birth for the patient in all cases. Any pregnancies that do not result in a live birth, such as a pregnancy termination or an ectopic pregnancy, were classified as a clinical miscarriage.There were several key assumptions in the model. In this model, the patients who underwent assisted reproduction treatment were simulated analogously to the CESE-PGS trial. Patients in both treatment groups underwent one cycle of controlled ovarian stimulation, followed by IVF with PGT-A or IVF with no selection by genetic status and transfer of a maximum of three selected embryos. Intracytoplasmic sperm injection (ICSI) was used in all IVF procedures. In the PGT-A group, three good-quality blastocysts that had been selected by using morphologic criteria underwent trophectoderm biopsy based on the next-generation sequencing platform (Illumina Next Seq 550 or Ion PGM/Proton). For safety reasons, only euploid blastocyst was chosen for transfer in the PGT-A group. All the obtained embryos were cryopreserved and single frozen-embryo transfers were performed each time in the two groups.The main inclusion criteria of the CESE-PGS trial were as follows: eligible patients were 20–37 years old and the availability of three or more good-quality blastocysts. Exclusion criteria as a known uterine abnormality, the presence of a contraindication to live birth, a plan to undergo PGT-M or PGT-SR, or the use of donated sperm or oocytes to achieve live birth. We characterize the population to which our results may be generalized (eTable 